5-Dec-2016
Médecins Sans Frontières
International medical humanitarian organisation Médecins Sans Frontières (MSF), along with other health groups, reiterated concerns about harmful intellectual property provisions in the proposed agreement that would increase market monopolies for pharmaceutical corporations and delay or block access to affordable generic medicines.
22-Nov-2016
Huffington Post
Experts have been warning for years that Canada’s trade deal with the European Union would add billions to the cost of pharmaceuticals in Canada, but the government itself apparently did not study the issue.
8-Nov-2016
Pharma in Focus
US reports that data exclusivity for biologics in Australia could still be extended to 12 years via the TPP trade deal have got local activists up in arms.
21-Oct-2016
Hindu Business Line
India and the US continued to differ on the issue of intellectual property rights (IPR) norms in their bilateral trade and investment policy discussions
13-Oct-2016
Don’t trade our lives away
Member countries must consider the impact of RCEP on access to medicines in developing countries
11-Oct-2016
South China Morning Post
Affordable generics have transformed medical treatment, yet intellectual property provisions in a China-led regional trade deal could block access to life-saving drugs for millions in Africa and Asia
28-Sep-2016
Corporate Europe Observatory
Big Pharma is everything but shy when it comes to lobbying EU policy-makers. But what exactly are these groups lobbying for in TTIP?
20-May-2016
East Asia Forum
Of the RCEP negotiating countries, it is India, rather than China, that has been the most outspoken in opposing US-style trade rules.